Barclays PLC Krystal Biotech, Inc. Call Options Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
Call Options
2 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$635 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$458 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$422 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$234 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$159 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.13B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...